A journalist for more than two decades’ standing, Elizabeth has covered the pharma, biotech and medtech sectors in a variety of roles over the years. She moved to Scrip in 2023 from Vantage, where she specialised in cardiovascular therapies as well as obesity, diabetes and related metabolic disorders. Elizabeth has a degree in biochemistry from the University of Surrey.
Latest from Elizabeth Cairns
Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.
Until the full data are released, it is difficult to weigh ANCHOR.
But biotechs are still having to price their offerings lower than they had planned.
The FDA has placed zetomipzomib on clinical hold a year after Kezar decided to focus solely on the product.
Once the deal with Sanofi closes, the rare disease drug will become one of Recordati’s fastest forecast sellers.
The Swiss group’s head of cardiovascular, renal and metabolism aims to speed its incretins to market, and tackle the plateauing of weight loss and muscle wastage through combinations.